<DOC>
	<DOCNO>NCT00159458</DOCNO>
	<brief_summary>The purpose study find combination gemcitabine oxaliplatin chemotherapy effective reduce eliminate tumor ( ) patient recurrent metastatic breast cancer . Gemcitabine chemotherapy drug approve U.S. Food Drug Administration ( FDA ) treatment pancreatic lung cancer ; oxaliplatin chemotherapy drug approve FDA treatment colon cancer . Neither gemcitabine oxaliplatin approve treatment breast cancer . However , drug show decrease size breast cancer tumor .</brief_summary>
	<brief_title>Clinical Trial Gemcitabine Oxaliplatin Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven dx recurrent metastatic breast cancer Must receive least 1 3 prior chemotherapy regimens recurrent metastatic breast cancer . Patients relapse within 12 month complete adjuvant chemotherapy 2 prior regimen metastatic disease . Patients relapse within 12 month complete adjuvant chemotherapy contain anthracycline taxane , require prior chemotherapy metastatic disease . Unidimensionally measurable dz ( RECIST ) At least 18 yrs age SWOG PS 02 AGC great equal 1.5 ; platelet great equal 100,000 ; Hgb great equal 8.0 Total bilirubin less equal 2 x uln ; SGOT and/or SGPT alk phos 2.5 x uln Creatinine le equal 2.0 Fully recover acute toxicity secondary prior tx Signed informed consent ( include HIPAA authorization ) Peripheral neuropathy grade 01 Exclusion Criteria Prior tx gemcitabine oxaliplatin . Prior tx cisplatin carboplatin allow complete &gt; 12 mo prior enrollment . Underlying medical , psychiatric , social condition would preclude patient receive tx Peripheral neuropathy great equal Gr 2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>